Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation

Clinical trial NCT06744647 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06744647
Sponsor: Alexion Pharmaceuticals, Inc.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Antibody-Mediated Rejection Kidney Transplantation Biopsy-proven Histologic Scores AMR

Start date: 2025-03-07
Primary completion: 2027-10-11
Enrollment: 47

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.